Thales to Provide Mobile Driver Licenses to State of Florida
13.10.2020 16:00:00 EEST | Business Wire | Press release
The State of Florida will be the first state in the United States to provide mobile Driver Licenses with leading-edge security mechanisms, fully compliant with rigorous national and international standards. Thales will supply the Florida Department of Highway Safety and Motor Vehicles with mobile Driver License verification services, as well as a mobile Driver License solution for residents.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005021/en/
(Photo: Business Wire)
In 2021, Florida residents will be able to apply for new mobile Driver Licenses that are easily accessible on a variety of devices, including smartphones and tablets. These mobile Driver Licenses meet the national and international standards from the American Association of Motor Vehicle Administrators and the International Organization for Standardization, meaning they can be used across the United States and internationally.
These new mobile Driver Licenses have the same validity as traditional driver’s licenses to verify identity, including proof of age and driving privileges. It also provides an additional role as a strong authentication tool, enabling Floridians to securely prove who they are online for a variety of services.
Now, to complement the traditional use of driver licenses to prove their identity, Florida residents will be able to simply activate their mobile identification application, select the type of verification needed, and hold up their mobile device. The mobile device never leaves the owners hand, making it a contact-free and convenient way to show ID.
“I’m excited for this innovation project that will make the state of Florida a national leader in offering secure and trusted mobile identification, which is a priority for our Governor, Ron DeSantis,” said Terry L. Rhodes, Executive Director of the Florida Department of Highway Safety and Motor Vehicles. “We have made a sustained commitment to the modernization of nearly every aspect of what our department does and how customers access our services, and Thales will be a great partner as Florida now steps into the future of mobile identification.”
“As ID fraud becomes more frequent and sophisticated, we made it a priority to reinforce ID verification by adding extra software security technologies. In the future, enterprises such as airports, hotels, car rental companies etc, in Florida will be able to rely on Thales to identify customers, while guaranteeing their privacy”, said Tony Lo Brutto, VP NORAM, Identity and Biometric Solutions at Thales.
These mobile Driver Licenses are harder to counterfeit, as they host a secure digitized credential whose authenticity can be checked rather than simply displaying a digital image of a driver license that could be easily manipulated.
For stronger privacy, users of mobile Driver Licenses control what information is displayed from the app depending on the context. For example, to enter a casino it only needs to show that the individual is old enough and the mobile Driver License will just display that information – not the individual’s name, date of birth, or address.
The Florida mobile Driver License program builds on Thales’ strong foundation of supporting state identity programs for 11 other U.S. states and five Canadian provinces.
Note to Editors
Thales, a leader in mobile driver’s license technology, successfully conducted the first U.S. mobile Driver’s License or Digital Driver’s License pilots across multiple states through a partnership and grant awarded in 2016 by the U.S. National Institute of Standards and Technology. Thales has recently been nationally recognized for the Digital ID Wallet, which incorporates the mobile Driver’s License solution, by Frost & Sullivan and ABI Research
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019.
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Download HD pictures
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005021/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Digital Identity & Security
Vanessa Viala
+33 6 07 34 00 34
Vanessa.viala@thalesgroup.com
Thales, Media Relations
USA
Adam Kostecki
+1 (703) 838-5645
adam.kostecki@us.thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
